Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 48.83 thousand shares for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2016-11-03
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2016-09-30 was 25.00K shares.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2016-06-30 was 0.00 shares.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2016-03-31 was 23.83K shares.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2014 was 9.00K shares, a 85.96% decline from fiscal 2013.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2013 was 64.08K shares, a 2.77% increase from fiscal 2012.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2012 was 62.35K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2016-09-30 | 25.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | 25.00K shares derived: sum of 2 quarters · filed 2016-11-03 | 48.83K shares 10-Q · filed 2016-11-03 | |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | 23.83K shares 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | 23.83K shares 10-Q · filed 2016-05-04 | |||
| 2014-12-31 | 9.00K shares 10-K · filed 2015-03-13 | |||
| 2013-12-31 | 64.08K shares 10-K · filed 2015-03-13 | |||
| 2012-12-31 | 62.35K shares 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |